BioCentury
ARTICLE | Clinical News

Innate Pharma preclinical data

May 6, 2013 7:00 AM UTC

In mouse xenograft models of lymphoma, twice-weekly 300 µg injections of 1 of 2 IPH41 mAbs significantly increased median survival vs. IgG1-treated controls. Data were presented at the American Associ...